AMA Publishes New CPT Codes for Coronavirus Vaccines

A new update published by the American Medical Association (AMA) includes new vaccine-specific codes to report on immunizations for Covid-19.

These new codes were established by AMA working closely alongside the Centers for Disease Control and Prevention. The CPT Editorial Panel approved a CPT code unique for each of the two Coronavirus vaccines and administration codes unique for each vaccine.

The outcome of this is better tracking, reporting, and analysis that supports future planning and allocation that are backed by data.

AMA President Susan R. Bailey, M.D., states, “Correlating each coronavirus vaccine with its own unique CPT code provides analytical advantages to help track, allocate and optimize resources as an immunization program ramps up in the United States.”

The new Category I CPT codes and long descriptors for the vaccine products are as follows.

• 91300
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosages, diluent reconstituted, for intramuscular use

• 91301
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosages, for intramuscular use

Also, the CPT Editorial Panel has worked alongside the Centers for Medicare & Medicaid Services to create new vaccine administration codes specific to the Covid-19 vaccine and the correlating specific dose in the required schedule. This will provide tracking of each vaccine code even in instances where the vaccine was given to the patient for free.

The new vaccine administration CPT codes and long descriptors are as follows.

• 0001A
  • Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosages, diluent reconstituted; first dose

• 0002A
  • Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 30 mcg/0.3mL dosages, diluent reconstituted; second dose

• 0011A
  • Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosages; first dose

• 0012A
  • Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 100 mcg/0.5mL dosages; second dose

All of the new vaccine-specific CPT codes listed in this article will be available for use and effective upon each new coronavirus vaccine receiving Emergency Use Authorization or approval from the Food and Drug Administration. The AMA website will provide the short and medium descriptors for the new vaccine-specific CPT codes to be accessed and several other recent modifications to the CPT code set that have aided the public health’s response to Covid-19.

Sources: AMA